COVID-19

NCRAS is undertaking a number of core projects aimed at providing near real-time data for England to support clinical and policy decision making in relation to the COVID pandemic. These are:

  • A proxy registration dataset for 2020, aimed at supporting near-real time analysis in relation to COVID and which will be available through the Office for Data Release
  • A RTDS dashboard which is aimed at providing a suite of metrics of radiotherapy relevant to COVID-19 which are designed to support decision making on cancer services. This is now available via the Cancerstats2 platform (for those with nhs.net access only at the current time)
  • A SACT dashboard aimed at providing a suite of metrics of chemotherapy relevant to COVID-19 which are designed to support decision making on cancer services. This is now available via the Cancerstats2 platform (for those with nhs.net access only at the current time)

NCRAS has also supported a number of requests for data to help manage and understand the impact on cancer and non-cancer care and outcomes during the COVID-19 pandemic. These datasets are made available publicly below to support further planning and research.

Cancer datasets:

    • National data on TWW conversion and detection rates for up to 14 tumour types, providing an insight into referral activities and their contribution to diagnostic pathways. The percentage of urgent suspected cancer referrals which result in cancer diagnosis has decreased from 10.8% for 2009/10 to 7.1% for 2018/19 in England. In the same period, the percentage of cases receiving treatment for cancer which resulted from an urgent suspected cancer referral increased from 42.3% to 53.1%.
      • More data on conversion and detection rates broken down by different metrics is available in two interactive tools comparing geographies and cancer sites.
    • A breakdown of age, stage, sex and cancer type for cancers diagnosed via the Two Week Wait (TWW) pathway in 2016-2018.
      • More information on NCRAS’s Routes to Diagnosis publications is available here.
    • The conversion rate of urgent referrals for suspected urological cancers (TWW), broken down by age and diagnosed cancer type for referrals from 2013/14 to 2018/19.
    • The weekly volume of radiotherapy episodes from 1st October 2018 up to 31st May 2020 for rectal cancer, by gender, age band, region and prescribed total dose and prescribed total fractions (short and long course)
    • The weekly counts of radiotherapy episodes and attendances up to May 2020 by cancer type, intent, and breast cancer dose fractionation.
      • More data on radiotherapy activity in hospitals in England is available in an interactive tool

Cancer papers:

      • Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Includes information on:
        • proportion of all diagnoses made via two-week-wait pathway, with a breakdown by cancers diagnosed via this pathway by age and cancer stage, diagnostic conversion rate, and average annual referrals for 2013-2016 (Table 1)
        • age-stratified and stage-stratified information on routes to diagnosis and conversion rates for 20 common tumour types referred in 2013-2016 (Supplementary Table 2)
        • estimated impact on 10-year net survival of differing periods of diagnostic delay to cancer treatment for patients in England for 20 common tumour types diagnosed in 2008–17 at age 30 years and older (Supplementary Table 3) and broken down by stage and age (Supplementary Table 4)
      • Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Includes information on:
        • Estimated reduction in 5-year net survival due to a 6-month delay to surgery for 13 cancer types, by tumour stage and age of diagnosis (Table 2)
        • Estimated reduction in 5-year survival for 31 cancer types/subtypes, by tumour stage and age of diagnosis, due to delays in surgery (Supplementary Table 3)
      • Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Includes information on:
        • Estimated reduction in 10-year net colorectal cancer survival by age and stage due to delays in the diagnostic pathway (Table 1)

These three cancer modelling papers utilised 5- and 10- year crude and net survival by stage, cancer site and receipt of major surgical resection for 2013-2017.

Non-cancer datasets:

    • Estimates of the size of the general population with polypharmacy broken down by age group between October 2018 and September 2019. Polypharmacy has been estimated using the number of prescriptions per person per month, and as the proportion of people with 10+ drugs per person per month.
    • Estimates of the size of the general population with cardiac polypharmacy broken down by age group in July 2019. Polypharmacy has been estimated using the number of unique cardiac drugs prescribed for a specific purpose dispensed per patient in July 2019, and as the number of cardiac prescriptions per patient in July 2019.

More information on the range of outputs NCRAS regularly produces, which may also provide relevant information to support planning and decision making during the COVID-19 period, is available here